molecules of the month


venetoclax prodrug with reduced food effect

enhanced bioavailability in healthy volunteers

from venetoclax heterocycle N-alkylation

Mol. Cancer. Ther. Mar. 30, 2021

AbbVie, North Chicago, IL

Structure of the AbbVie BCL-2 inhibitor prodrug (ABBV-167)
1 min read

The AbbVie BCL-2 inhibitor prodrug (ABBV-167) is a phosphate prodrug of venetoclax used for treatment of chronic lymphocytic leukemia (CLL). This molecule has an interesting prodrug mechanism, masking an azaindole heterocycle through heterocycle N-alkylation. By improving the solubility, the dose needed of this prodrug relative to parent was greatly reduced, nicely illustrated with pill pictures in the manuscript. A clinical study on healthy volunteers revealed that both solid and liquid dosage forms of ABBV-167 significantly improve the bioavailability of venetoclax under fasted conditions and reduce the food effect with respect to venetoclax.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: